CHRYSALIN Trademark

Trademark Overview

On Wednesday, September 9, 2020, a trademark application was filed for CHRYSALIN with the United States Patent and Trademark Office. The USPTO has given the CHRYSALIN trademark a serial number of 90169585. The federal status of this trademark filing is REGISTERED as of Tuesday, September 17, 2024. This trademark is owned by Chrysalis BioTherapeutics, Inc.. The CHRYSALIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetic foot ulcers; Pharmaceutical preparations for accelerating healing of human tissue; Therapeutic gels intended for topical use on skin and mucous membranes, intended to accelerate the healing of skin surface wounds and diabetic foot ulcers; Pharmaceuticals for the treatment of acute radiation syndrome; Pharmaceuticals for the treatment of COVID-19; Pharmaceutical products for the prevention and treatment of Degenerative Brain Diseases and Traumatic Brain Injury (TBI)
chrysalin

General Information

Serial Number90169585
Word MarkCHRYSALIN
Filing DateWednesday, September 9, 2020
Status700 - REGISTERED
Status DateTuesday, September 17, 2024
Registration Number7507922
Registration DateTuesday, September 17, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 13, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetic foot ulcers; Pharmaceutical preparations for accelerating healing of human tissue; Therapeutic gels intended for topical use on skin and mucous membranes, intended to accelerate the healing of skin surface wounds and diabetic foot ulcers; Pharmaceuticals for the treatment of acute radiation syndrome; Pharmaceuticals for the treatment of COVID-19; Pharmaceutical products for the prevention and treatment of Degenerative Brain Diseases and Traumatic Brain Injury (TBI)

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 15, 2020
Primary Code005
First Use Anywhere DateTuesday, July 31, 2012
First Use In Commerce DateTuesday, July 31, 2012

Trademark Owner History

Party NameChrysalis BioTherapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressGalveston, TX 77550
Party NameChrysalis BioTherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGalveston, TX 77550
Party NameChrysalis BioTherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGalveston, TX 77550

Trademark Events

Event DateEvent Description
Saturday, September 12, 2020NEW APPLICATION ENTERED
Thursday, October 15, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 25, 2021ASSIGNED TO EXAMINER
Thursday, March 11, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 13, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 13, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 8, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, December 3, 2021SOU TEAS EXTENSION RECEIVED
Friday, December 3, 2021SOU EXTENSION 1 FILED
Friday, December 3, 2021SOU EXTENSION 1 GRANTED
Tuesday, December 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 7, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 7, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, December 7, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 9, 2022SOU TEAS EXTENSION RECEIVED
Monday, May 9, 2022SOU EXTENSION 2 FILED
Monday, May 9, 2022SOU EXTENSION 2 GRANTED
Wednesday, May 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 11, 2022SOU TEAS EXTENSION RECEIVED
Friday, November 11, 2022SOU EXTENSION 3 FILED
Friday, November 11, 2022SOU EXTENSION 3 GRANTED
Tuesday, November 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 6, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, June 6, 2023SOU EXTENSION 4 FILED
Tuesday, June 6, 2023SOU EXTENSION 4 GRANTED
Thursday, June 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 30, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 30, 2023SOU EXTENSION 5 FILED
Thursday, November 30, 2023SOU EXTENSION 5 GRANTED
Friday, December 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 5, 2024USE AMENDMENT FILED
Wednesday, June 5, 2024TEAS STATEMENT OF USE RECEIVED
Friday, July 19, 2024STATEMENT OF USE PROCESSING COMPLETE
Friday, July 19, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, August 11, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sunday, August 11, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 17, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 17, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

chrysalin treatment pharmaceutical preparations skin pharmaceuticals brain intended foot healing ulcers